These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 3981034

  • 1. Mast cell depletion in murine chronic graft-versus-host disease.
    Claman HN.
    J Invest Dermatol; 1985 Apr; 84(4):246-8. PubMed ID: 3981034
    [Abstract] [Full Text] [Related]

  • 2. Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis.
    Claman HN, Jaffee BD, Huff JC, Clark RA.
    Cell Immunol; 1985 Aug; 94(1):73-84. PubMed ID: 4016962
    [Abstract] [Full Text] [Related]

  • 3. Mast cell "disappearance" in chronic murine graft-vs-host disease (GVHD)-ultrastructural demonstration of "phantom mast cells".
    Claman HN, Choi KL, Sujansky W, Vatter AE.
    J Immunol; 1986 Sep 15; 137(6):2009-13. PubMed ID: 3745920
    [Abstract] [Full Text] [Related]

  • 4. Cutaneous mast cell depletion and recovery in murine graft-vs-host disease.
    Choi KL, Giorno R, Claman HN.
    J Immunol; 1987 Jun 15; 138(12):4093-101. PubMed ID: 2953799
    [Abstract] [Full Text] [Related]

  • 5. Effect of graft-versus-host disease on anti-tumor immunity.
    Schreiber KL, Forman J.
    J Immunol; 1990 Mar 01; 144(5):2018-26. PubMed ID: 1968493
    [Abstract] [Full Text] [Related]

  • 6. Mast cells in murine graft-versus-host disease: a model of immunologically induced fibrosis.
    Choi KL, Claman HN.
    Immunol Ser; 1989 Mar 01; 46():641-51. PubMed ID: 2488873
    [No Abstract] [Full Text] [Related]

  • 7. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation.
    Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC.
    J Immunol; 2002 Mar 15; 168(6):3088-98. PubMed ID: 11884483
    [Abstract] [Full Text] [Related]

  • 8. Target antigens determine graft-versus-host disease phenotype.
    Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD.
    J Immunol; 2004 Nov 01; 173(9):5467-75. PubMed ID: 15494494
    [Abstract] [Full Text] [Related]

  • 9. Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease.
    Murphy GF, Sueki H, Teuscher C, Whitaker D, Korngold R.
    J Invest Dermatol; 1994 Apr 01; 102(4):451-61. PubMed ID: 7908682
    [Abstract] [Full Text] [Related]

  • 10. Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease.
    Levi-Schaffer F, Goldenhersh MA, Segal V, Nagler A.
    Bone Marrow Transplant; 1997 Apr 01; 19(8):823-8. PubMed ID: 9134176
    [Abstract] [Full Text] [Related]

  • 11. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems.
    Jaffee BD, Claman HN.
    Cell Immunol; 1983 Apr 01; 77(1):1-12. PubMed ID: 6220812
    [Abstract] [Full Text] [Related]

  • 12. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.
    Zhang Y, McCormick LL, Gilliam AC.
    J Invest Dermatol; 2003 Oct 01; 121(4):713-9. PubMed ID: 14632186
    [Abstract] [Full Text] [Related]

  • 13. Sequential expression of adhesion and costimulatory molecules in graft-versus-host disease target organs after murine bone marrow transplantation across minor histocompatibility antigen barriers.
    Eyrich M, Burger G, Marquardt K, Budach W, Schilbach K, Niethammer D, Schlegel PG.
    Biol Blood Marrow Transplant; 2005 May 01; 11(5):371-82. PubMed ID: 15846291
    [Abstract] [Full Text] [Related]

  • 14. Mast Cells Are Mediators of Fibrosis and Effector Cell Recruitment in Dermal Chronic Graft-vs.-Host Disease.
    Strattan E, Palaniyandi S, Kumari R, Du J, Hakim N, Huang T, Kesler MV, Jennings CD, Sturgill JL, Hildebrandt GC.
    Front Immunol; 2019 May 01; 10():2470. PubMed ID: 31681336
    [Abstract] [Full Text] [Related]

  • 15. Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease.
    Ferrara J, Guillen FJ, Sleckman B, Burakoff SJ, Murphy GF.
    J Invest Dermatol; 1986 Apr 01; 86(4):371-5. PubMed ID: 3528309
    [Abstract] [Full Text] [Related]

  • 16. Synergism between T and non-T cells in the in vivo induction and in vitro expression of graft-vs.-host disease-induced natural suppressor cells.
    Maier T, Holda JH, Claman HN.
    J Exp Med; 1985 Sep 01; 162(3):979-92. PubMed ID: 3161977
    [Abstract] [Full Text] [Related]

  • 17. Regulation of the functional activity of mast cells and fibroblasts by mononuclear cells in murine and human chronic graft-vs.-host disease.
    Levi-Schaffer F, Segal V, Barak V, Rubinchik E, Nagler A.
    Exp Hematol; 1997 Mar 01; 25(3):238-45. PubMed ID: 9091300
    [Abstract] [Full Text] [Related]

  • 18. Immunosuppression and lymphoid hypoplasia associated with chronic graft versus host disease is dependent upon IFN-gamma production.
    Klimpel GR, Annable CR, Cleveland MG, Jerrells TR, Patterson JC.
    J Immunol; 1990 Jan 01; 144(1):84-93. PubMed ID: 2104894
    [Abstract] [Full Text] [Related]

  • 19. Histamine release from mouse and rat mast cells cultured with supernatants from chronic murine graft-vs-host splenocytes.
    Levi-Schaffer F, Mekori YA, Segal V, Claman HN.
    Cell Immunol; 1990 Apr 15; 127(1):146-58. PubMed ID: 1690607
    [Abstract] [Full Text] [Related]

  • 20. Mast Cell Involvement in Fibrosis in Chronic Graft-Versus-Host Disease.
    Strattan E, Hildebrandt GC.
    Int J Mol Sci; 2021 Feb 27; 22(5):. PubMed ID: 33673565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.